Cardiovascular Device Update articles from February 2006

Cardiovascular Device Update archives from February 2006

Cardio firms attract interested listeners at investor gathering.
February 1, 2006... Cardio firms attract interested listeners at investor gathering By JIM STOMMEN CDU Executive Editor SAN FRANCISCO -- Cardiovascular device firms of every shape and size -- small caps, medium caps, big caps, early stage,...

Big year for 'transformational activity,' says Braunstein.(Conference news)(Brief article)
February 1, 2006... Big year for 'transformational activity,' says Braunstein Doug Braunstein, head of Americas investment banking for JPMorgan Chase, said in delivering his welcoming remarks at the 24th annual JPMorgan Healthcare Conference in San Francisco...

Biosite cites developments in cardiac testing sector.
February 1, 2006... Biosite cites developments in cardiac testing sector Those involved with the medical diagnostics sector like to refer to how diagnostics -- despite accounting for under 5% of hospital costs and less than 2% of total healthcare expenditures...

Boston Sci's $27.2B offer wins out in Guidant sweepstakes.(Company overview)
February 1, 2006... Boston Sci's $27.2B offer wins out in Guidant sweepstakes By HOLLAND JOHNSON CDU Associate Managing Editor It appears that the saga of who will buy troubled cardiac rhythm management (CRM) firm Guidant (Indianapolis) is finally...

CUSTOM II launch grows Xtent focus on multiple stenting.
February 1, 2006... CUSTOM II launch grows Xtent focus on multiple stenting By DON LONG CDU Managing Editor Clinical trial testing of drug-eluting stent (DES) devices over the remainder of this decade will seek to asses new, more complex uses and...

Mechanical valve to be put to lower drug regimen test.
February 1, 2006... Mechanical valve to be put to lower drug regimen test By DON LONG CDU Managing Editor Cardiovascular therapies often require patients to make very tough choices. In the category of heart valve replacement, the choice is...

International report.
February 1, 2006... International report Biophan Europe cites development progress A CDU Staff Report Biophan Europe (Castrop-Rauxel, Germany), the European subsidiary of Biophan Technologies (West Henrietta, New York), has reported a series of...

Acquisitions.
February 1, 2006... Acquisitions * ATS Medical (Minneapolis) developer, manufacturer and marketer of cardiac surgery products and services, reported a definitive agreement under which it will acquire all the outstanding shares of privately held 3F...

Business developments.
February 1, 2006... Business developments Coverage proposal may impact ICDs A proposed Centers for Medicare & Medicaid Services (CMS; Baltimore) national coverage decision involving Cambridge Heart's (Bedford, Massachusetts) Microvolt T-Wave Alternans...

New report offers overview of cardiovascular tech sector.
February 1, 2006... New report offers overview of cardiovascular tech sector Advances in Cardiovascular Technology: State of the Industry and Emerging Markets, Vol. 3, is now available from the publishers of Cardiovascular Device Update, Medical Device Daily...

Agreements.
February 1, 2006... Agreements * Affymetrix (Santa Clara, California) reported entering into a five-year collaboration with Duke University (Durham, North Carolina) to analyze genomic information across large patient samples. Duke researchers will use...

Market Updates.
February 1, 2006... Market Updates CDRH beefing up post-market efforts In the wake of the multitude of recalls in 2005 of implantable systems -- primarily pacemakers and implantable cardioverter defibrillators -- the FDA's Center for Devices and...

Personnel File.
February 1, 2006... Personnel File Daniel Sutherby joined Abiomed (Danvers, Massachusetts) as CFO. He previously was with PerkinElmer, most recently as corporate vice president, investor relations, corporate communications and risk management. Charles Haaser,...

Product Pipeline.
February 1, 2006... Product Pipeline Roche test is okayed for risk assessment Roche Diagnostics (Indianapolis) has received FDA clearance for what the company says is the first and only natriuretic peptide test to be green-lighted by the FDA for risk...